COVID-19Regulatory

Coronavirus pandemic: Updates from around the world

June 4, 2020 / By Joshua BerlingerBrett McKeehanLaura Smith-Spark and Peter Wilkinson, CNN

Second medical journal retracts coronavirus paper over questions about data source – From CNN’s Maggie Fox

The New England Journal of Medicine retracted a coronavirus study on Thursday, saying it could not guarantee the validity of the data used in the study.

It was the second journal to retract a coronavirus study that had been conducted using data provided by Surgisphere, which aggregated global health information for the research. Earlier Thursday, The Lancet also retracted a coronavirus study.

Both journals had signaled their worries in “expression of concern” earlier this week.

“Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article, ‘Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.’ We therefore request that the article be retracted. We apologize to the editors and to readers of the Journalforthe difficulties that this has caused,” Dr. Mandeep Mehra of Brigham and Women’s Hospital Heart and Vascular Center in Boston, Surgisphere founder Dr. Sapan Desai and colleagues wrote in the retraction letter.

The study had found that certain heart disease drugs, including ACE inhibitors, didn’t worsen the risk of death for coronavirus patients.

READ THE REST HERE

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button